FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to derivatives of nucleosides, based on them compositions and methods of treating liver disorders, mediated by Flaviviridae infection, including hepatitis C. The said derivatives of nucleosides include 
, where R1 represents hydroxyl, amino or benzylamino; and R2 represents hydrogen, 
, 
, 
or 
, and when R1 represents hydroxyl, R2 is different from hydrogen, 
and, , when R1 represents benzylamino, R2 is different from 
.
EFFECT: novel effective antiviral compounds are claimed.
43 cl, 64 tbl, 18 ex, 6 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| SPECIFIC DIARYLHYDANTOIN AND DIARYLTHIODIARYL COMPOUNDS | 2010 |
|
RU2548918C2 |
| IDENTIFICATION OF PATIENTS' REACTION TO ADMINISTRATION OF S1P RECEPTOR MODULATOR | 2013 |
|
RU2785736C2 |
| GLUCURONIDATED ACETAMINOPHEN AS MARKER OF LIVER DISORDERS | 2009 |
|
RU2555331C2 |
| HEMI-SULPHATE NUCLEOTIDE SALT FOR TREATMENT OF HEPATITIS C VIRUS | 2018 |
|
RU2787616C2 |
| PHARMACEUTICAL COMPOSITIONS BASED ON SHK AND METHODS FOR THEIR PRODUCTION AND USE | 2012 |
|
RU2637085C2 |
| DANTROLENE PRODRUGS AND METHODS OF THEIR USE | 2018 |
|
RU2815017C2 |
| COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS | 2007 |
|
RU2466729C2 |
| COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS | 2007 |
|
RU2525392C2 |
| PHARMACEUTICAL COMPOSITIONS | 2018 |
|
RU2783865C2 |
| PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF HELICOBACTER PYLORI | 2014 |
|
RU2671400C2 |
